Trial Profile
A Two-Cohort Randomized Phase II, Double-Blind, Parallel Group Study in Patients With Active Rheumatoid Arthritis Evaluating the Efficacy and Safety of GDC-0853 Compared With Placebo and Adalimumab in Patients With an Inadequate Response to Previous Methotrexate Therapy (Cohort 1) and Compared With Placebo in Patients With an Inadequate Response to Previous TNF Therapy (Cohort 2)
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Fenebrutinib (Primary) ; Adalimumab
- Indications Rheumatoid arthritis
- Focus Adverse reactions; Proof of concept; Therapeutic Use
- Acronyms ANDES
- Sponsors Genentech
- 09 Apr 2020 Results published in the Arthritis and Rheumatology
- 15 Jun 2019 Results presented at the 20th Annual Congress of the European League Against Rheumatism
- 15 Jun 2019 Results presented at the 20th Annual Congress of the European League Against Rheumatism